VANCOUVER, British Columbia, Jan. 23, 2019 (GLOBE NEWSWIRE) -- On Thursday, Jan. 24, the Fraser Institute will release a new study on prescription drug-pricing in Canada.
Pharmaceutical Regulation, Innovation, and Access to New Drugs: An International Perspective spotlights plans by the federal government to lower drug costs and reveals how those planned changes could affect Canadian patients and innovation in the pharmaceutical industry.
A news release with additional information will be issued via GlobeNewswire at 5:00 a.m. (Eastern) on Jan. 24.
MEDIA CONTACTS:
Steven Globerman, Senior Fellow
Fraser Institute
Bacchus Barua, Associate Director, Health Policy Studies
Fraser Institute
To arrange media interviews or for more information, please contact:
Bryn Weese
Senior Media Relations Specialist, Fraser Institute
(604) 688-0221 ext. 589
bryn.weese@fraserinstitute.org
Follow the Fraser Institute on Twitter | Like us on Facebook
The Fraser Institute is an independent Canadian public policy research and educational organization with offices in Vancouver, Calgary, Toronto, and Montreal and ties to a global network of think-tanks in 87 countries. Its mission is to improve the quality of life for Canadians, their families and future generations by studying, measuring and broadly communicating the effects of government policies, entrepreneurship and choice on their well-being. To protect the Institute’s independence, it does not accept grants from governments or contracts for research. Visit www.fraserinstitute.org